Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (symbol: BLCO) is a prominent player in the vision care industry based in Madrid, Spain. Originally part of Bausch Health, Bausch + Lomb became a public company in 2022. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals.
Vision Care Segment: This segment covers contact lenses and ocular health products. Bausch + Lomb holds a 10% market share in contact lenses, and its portfolio includes popular brands such as Biotrue and Lumify.
Surgical Segment: This includes intraocular lenses and equipment for cataract and vitreoretinal surgeries. The company also provides a range of surgical instruments, making it a comprehensive provider in the surgical eye care market.
Ophthalmic Pharmaceuticals: Bausch + Lomb offers over 100 products, including Xipere, Vyzulta, and Lotemax, which are designed to treat various eye conditions. This extensive lineup makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market.
With a strong commitment to innovation and quality, Bausch + Lomb continuously works on new projects and partnerships to enhance its product offerings. The company’s diverse portfolio and strategic initiatives ensure its significant role in the vision care industry.
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) has announced the FDA approval of the TENEO Excimer Laser Platform for LASIK vision correction surgery. The platform offers accuracy, efficiency, and usability advantages, with unique features such as advanced eye tracking, high-speed laser, customizable touchscreen, and compact design. It is indicated for patients with myopic astigmatism up to -10.00 D MRSE, 22 years or older, and with stable refraction in the last 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference. Other company executives will also participate. A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
Rhea-AI Summary
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced the success of its ONE by ONE and Biotrue Eye Care Recycling programs, collecting 76,645,000 million units, or 464,100 pounds, of used contact lenses, eye care, and lens care materials in the United States. This initiative helps keep recyclable plastic and aluminum eye health packaging materials out of landfills and oceans, contributing to environmental sustainability and human health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
-
Rhea-AI Summary
Bausch + Lomb Corporation reported revenues of $1.007 billion in the third quarter of 2023, a 7% increase compared to the same period last year. The company's GAAP net loss was $84 million. Adjusted EBITDA was $187 million. Revenue growth was driven by the Vision Care and Surgical segments. The company raised its full-year revenue guidance to $4.035 - $4.085 billion and adjusted EBITDA guidance to $710 - $760 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
-
Rhea-AI Summary
Bausch + Lomb to present studies and data at the American Academy of Ophthalmology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
Rhea-AI Summary
Bausch + Lomb Corporation to release Q3 2023 financial results on Nov. 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
-
Rhea-AI Summary
Bausch + Lomb to present at AAOpt annual meeting, highlighting the results of a study on Blink Triple Care Lubricating Dry Eye Drops and data on MIEBO prescription eye drops and INFUSE Multifocal contact lenses. Educational events will also be hosted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
-
Rhea-AI Summary
Bausch + Lomb completes acquisition of XIIDRA for $2.5 billion, funded by $1.4 billion senior secured notes and $500 million term B loans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
Rhea-AI Summary
Bausch + Lomb completes acquisition of XIIDRA and other ophthalmology assets, expects to lead in prescription dry eye category. DED affects 739 million people worldwide, with the US market expected to grow at a double-digit compounded annual growth rate over the next five years. The acquisition was funded through an upfront payment of $1.75 billion in cash, with potential milestone obligations of up to $750 million based on sales thresholds and pipeline commercialization. XIIDRA and MIEBO are prescription eye drops used to treat dry eye disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
The current stock price of Bausch + Lomb Corporation (BLCO) is $17.65 as of January 30, 2025.
What is the market cap of Bausch + Lomb Corporation (BLCO)?
The market cap of Bausch + Lomb Corporation (BLCO) is approximately 6.3B.
What does Bausch + Lomb Corporation do?
Bausch + Lomb Corporation operates in the vision care industry, offering products in vision care, surgical, and ophthalmic pharmaceuticals segments.
When did Bausch + Lomb become a public company?
Bausch + Lomb became a public company in 2022 after spinning off from Bausch Health.
What are the primary segments Bausch + Lomb operates in?
The primary segments are vision care, surgical, and ophthalmic pharmaceuticals.
What are some key products in Bausch + Lomb's vision care segment?
Key products include Biotrue and Lumify, along with various contact lenses.
What does Bausch + Lomb offer in its surgical segment?
The surgical segment includes intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments.
What products are included in Bausch + Lomb's ophthalmic pharmaceuticals segment?
This segment features over 100 products, including Xipere, Vyzulta, and Lotemax, for treating various eye conditions.
Where is Bausch + Lomb Corporation headquartered?
The company is headquartered in Madrid, Spain.
What market share does Bausch + Lomb hold in the contact lenses market?
Bausch + Lomb controls 10% of the contact lenses market.
What makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market?
Its extensive lineup of over 100 eye care products helps Bausch + Lomb maintain a leadership position in the market.
What is Bausch + Lomb's commitment towards its products and services?
Bausch + Lomb is committed to innovation and quality, continuously enhancing its offerings through new projects and partnerships.
Bausch + Lomb Corporation
NYSE:BLCO
BLCO Rankings
BLCO Stock Data
6.28B
40.75M
88.41%
10.95%
0.36%
Medical Instruments & Supplies
Ophthalmic Goods
United States of America
VAUGHAN